LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

40.78 -1.35

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

40.32

Max

42.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

16M

-95M

Pardavimai

1.7M

203M

Pelnas, tenkantis vienai akcijai

-0.49

Pelno marža

-46.768

Darbuotojai

1,999

EBITDA

-12M

-111M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+44.56% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-762M

5.2B

Ankstesnė atidarymo kaina

42.13

Ankstesnė uždarymo kaina

40.78

Naujienos nuotaikos

By Acuity

29%

71%

80 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-14 23:40; UTC

Karštos akcijos

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

2025-05-14 23:33; UTC

Pagrindinės rinkos jėgos

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

2025-05-14 23:25; UTC

Pagrindinės rinkos jėgos

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

2025-05-14 23:25; UTC

Uždarbis

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

2025-05-14 22:58; UTC

Uždarbis

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

2025-05-14 21:35; UTC

Uždarbis

Cisco Systems Names Patterson as CFO, Patel as President

2025-05-14 23:59; UTC

Rinkos pokalbiai

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

2025-05-14 23:49; UTC

Rinkos pokalbiai

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

2025-05-14 23:48; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-05-14 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

2025-05-14 23:47; UTC

Rinkos pokalbiai

Gold Gains on Possible Technical Recovery -- Market Talk

2025-05-14 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

2025-05-14 23:10; UTC

Uždarbis

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

2025-05-14 23:07; UTC

Uždarbis

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

2025-05-14 23:00; UTC

Svarbiausios naujienos

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

2025-05-14 22:43; UTC

Uždarbis

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

2025-05-14 22:34; UTC

Uždarbis

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

2025-05-14 22:33; UTC

Uždarbis

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

2025-05-14 22:28; UTC

Uždarbis

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

2025-05-14 22:28; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

2025-05-14 22:27; UTC

Uždarbis

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

2025-05-14 22:27; UTC

Uždarbis

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

2025-05-14 22:23; UTC

Svarbiausios naujienos

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

2025-05-14 22:15; UTC

Uždarbis

Correction to Cisco Earnings Article -- WSJ

2025-05-14 21:48; UTC

Uždarbis

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

2025-05-14 21:37; UTC

Uždarbis

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

44.56% į viršų

12 mėnesių prognozė

Vidutinis 59.79 USD  44.56%

Aukščiausias 70 USD

Žemiausias 52 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

20

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

80 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.